All In Biotech

Drug Trial Radar · NCT05888831

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jun 6, 2023

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jun 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • BMS-986449Drug

    Specified dose on specified days

  • NivolumabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 4 years
  2. Number of participants with Adverse Events (AEs)Time frame: Up to approximately 4 years
  3. Number of participants with Serious Adverse Events (SAEs)Time frame: Up to approximately 4 years
  4. Number of participants with AEs leading to discontinuationTime frame: Up to approximately 4 years
  5. Number of deathsTime frame: Up to approximately 4 years

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • Local Institution - 0021

    Los Angeles, California

  • Local Institution - 0007

    New Haven, Connecticut

  • Local Institution - 0010

    Hackensack, New Jersey

  • Local Institution - 0022

    Lake Success, New York

  • Local Institution - 0016

    Brussels, Bruxelles-Capitale, Région de, Belgium

  • Local Institution - 0017

    Ghent, Oost-Vlaanderen, Belgium

  • Local Institution - 0003

    Bordeaux, France

  • Local Institution - 0002

    Villejuif, Paris, France

  • Local Institution - 0004

    Marseille, Provence-Alpes-Côte d'Azur Region, France

  • Local Institution - 0026

    Bergamo, Italy

  • Local Institution - 0025

    Roma, Italy

  • Local Institution - 0023

    Rozzano, Milano, Italy

  • Local Institution - 0024

    Siena, Tuscany, Italy

  • Local Institution - 0018

    Groningen, Netherlands

  • Local Institution - 0030

    Amsterdam, North Holland, Netherlands

  • Local Institution - 0014

    Madrid, Spain

  • Local Institution - 0011

    Madrid, Spain

  • Local Institution - 0015

    Málaga, Andalusia, Spain

  • Local Institution - 0013

    Badalona, Barcelona [Barcelona], Spain

  • Local Institution - 0012

    Pamplona, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.